Polycyclo Ring System Having The Additional Hetero Ring As One Of The Cyclos Patents (Class 514/210.21)
-
Patent number: 9809552Abstract: Compounds of the formula I in which R, X1, X2, X3, X4, R1, R2 and q have the meanings indicated in Claim 1, are inhibitors of fatty acid synthase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.Type: GrantFiled: February 24, 2014Date of Patent: November 7, 2017Assignee: MERCK PATENT GMBHInventors: Wolfgang Staehle, Christos Tsaklakidis, Manja Friese-Hamim, Birgitta Leuthner, Dirk Wienke
-
Patent number: 9809591Abstract: Compounds that are fatty acid synthesis modulators are provided. The compounds may be used to treat disorders characterized by disregulation of the fatty acid synthase function by modulating the function and/or the fatty acid synthase pathway. Methods are provided for treating such disorders including viral infections, such as hepatitis C infection, cancer and metabolic disorders.Type: GrantFiled: October 5, 2015Date of Patent: November 7, 2017Assignee: 3-V Biosciences, Inc.Inventors: Johan D. Oslob, Robert S. McDowell, Russell Johnson, Hanbiao Yang, Marc Evanchik, Cristiana A. Zaharia, Haiying Cai, Lily W. Hu
-
Patent number: 9796718Abstract: Provided are imidazopyrazine compounds, particularly including 6-(benzo[d]thiazol-5-yl)-N-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyrazin-8-amine, structure below, and methods and formulations for their use in inhibiting Spleen Tyrosine Kinase in treating conditions including B-cell lymphomas or leukemias and inflammatory conditions:Type: GrantFiled: October 13, 2015Date of Patent: October 24, 2017Assignee: Gilead Connecticut, Inc.Inventors: Scott A. Mitchell, Kevin S. Currie, Peter A. Blomgren, Jeffrey E. Kropf, Seung H. Lee, Jianjun Xu, Douglas G. Stafford, James P. Harding, Antonio J. M. Barbosa, Jr., Zhongdong Zhao, David M. Armistead, Soumya Mitra
-
Patent number: 9790201Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof (Formula (I)) in which m, X, R1, R2, R3 and R5 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.Type: GrantFiled: August 7, 2014Date of Patent: October 17, 2017Assignee: Takeda Pharmaceutical Company LimitedInventors: Sarah Bousba, Anne Goldby, Kerry Jenkins, Natasha Kinsella, Martin Teall
-
Patent number: 9782405Abstract: Heteroaryl pyridone and aza-pyridone compounds are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using heteroaryl pyridone and aza-pyridone compounds for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.Type: GrantFiled: November 17, 2015Date of Patent: October 10, 2017Assignee: Genentech, Inc.Inventors: James John Crawford, Daniel Fred Ortwine, BinQing Wei, Wendy B. Young
-
Patent number: 9783540Abstract: Compounds are provided that are modulators of the CCR2 receptor. The compounds have the general formula (I): and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activtation of CCR2 receptors.Type: GrantFiled: May 19, 2016Date of Patent: October 10, 2017Assignee: CHEMOCENTRYX, INC.Inventors: Junfa Fan, Jaroslaw Kalisiak, Rebecca M. Lui, Venkat Reddy Mali, Jeffrey P. McMahon, Jay P. Powers, Hiroko Tanaka, Yibin Zeng, Penglie Zhang
-
Patent number: 9777276Abstract: The present invention relates to the field of fibrosis and inflammation and more particularly to the use of ADAM12 (A Disintegrin and Metalloproteinase 12) inhibitors to prevent or treat inflammation-induced fibrosis. The present invention also relates to the use of ADAM12 as a marker for inflammation-induced fibrosis and to the ablation of ADAM12 expressing cells as therapeutic approach to interfere with the development of pro-fibrotic cells.Type: GrantFiled: September 5, 2014Date of Patent: October 3, 2017Assignee: INSTITUT PASTEURInventors: Lucie Peduto, Gerard Eberl
-
Patent number: 9771364Abstract: A process for preparation of a compound of Formula (I) is disclosed.Type: GrantFiled: December 29, 2014Date of Patent: September 26, 2017Assignee: WOCKHARDT LIMITEDInventors: Sanjeev Joshi, Sunil Bhaginath Jadhav, Vipul Rane, Satish Bhawsar, Prasad Keshav Deshpande, Ravindra Dattatraya Yeole, Mahesh Vithalbhai Patel
-
Patent number: 9765068Abstract: Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.Type: GrantFiled: January 13, 2016Date of Patent: September 19, 2017Assignee: Epizyme, Inc.Inventors: Kenneth W. Duncan, Richard Chesworth, Paula Ann Boriack-Sjodin, Michael John Munchhof, Lei Jin
-
Patent number: 9765091Abstract: The present invention relates to novel compounds of Formula (I), wherein M, A and Y are defined as in Formula (I); invention compounds are modulators of metabotropic glutamate receptors—subtype 4 (“mGluR4”) which are useful for the treatment or prevention of central nervous system disorders as well as other disorders modulated by mGluR4 receptors. The invention is also directed to pharmaceutical compositions and the use of such compounds in the manufacture of medicaments, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR4 is involved.Type: GrantFiled: July 11, 2011Date of Patent: September 19, 2017Assignees: Addex Pharma S.A., Merck Sharp & Dohme Corp.Inventors: Christelle Bolea, Sylvain Celanire, Lam Tang, Nigel J. Liverton, Philip Jones
-
Patent number: 9751884Abstract: The present invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, its preparation method, a pharmaceutical composition comprising the compound, and its use in manufacture of a medicament for treatment of a disease or disorder, wherein R1, R2, R5, R6, X, Y, Q, W, n1 and n2 are defined as those stated in the description.Type: GrantFiled: May 30, 2013Date of Patent: September 5, 2017Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Lan Xie, Xiaofeng Wang, Kuo-Hsiung Lee
-
Patent number: 9745271Abstract: Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, fibrotic disorders, cartilage (chondral) defects, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, and neurological conditions/disorders/diseases linked to overexpression of DYRK1A.Type: GrantFiled: March 20, 2015Date of Patent: August 29, 2017Assignee: Samumed, LLCInventors: John Hood, Sunil Kumar KC, David Mark Wallace, Gopi Kumar Mittapalli, Brian Joseph Hofilena, Chi Ching Mak, Venkataiah Bollu, Brian Eastman
-
Patent number: 9737533Abstract: The present invention relates to methods of treating various central nervous system disorders using novel triazolo[4,3-a]pyridine derivatives of Formula (I) wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (“mGluR2”), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.Type: GrantFiled: November 19, 2015Date of Patent: August 22, 2017Assignees: Janssen Pharmaceuticals. Inc., Addex Pharma SAInventors: Jose Maria Cid-Nunez, Daniel Oehlrich, Andres Avelino Trabanco-Suarez, Gary John Tresadern, Juan Antonio Vega Ramiro, Gregor James MacDonald
-
Patent number: 9738655Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.Type: GrantFiled: March 25, 2014Date of Patent: August 22, 2017Assignee: Bristol-Myers Squibb CompanyInventors: Donald J. P. Pinto, Charles G. Clarke, Leon M. Smith, II, Michael J. Orwat, Yoon Jeon, James R. Corte
-
Patent number: 9732060Abstract: The present invention provides novel compounds having a P2X3 and/or P2X2/3 receptor antagonistic activity. A compound of Formula (I): wherein Ra and Rb, and Rd and Re are taken together to form oxo or the like; R4a and R4b are hydrogen or the like; n is 1 or the like; R2 is aryl or the like; s and s? is 0 or the like; R9 and R9? are halogen or the like; R20a and R20b are hydrogen, alkyl or the like; u is 1 to 4; R13 is hydrogen or the like, or its pharmaceutically acceptable salt.Type: GrantFiled: June 13, 2014Date of Patent: August 15, 2017Assignee: SHIONOGI & CO., LTD.Inventor: Hiroyuki Kai
-
Patent number: 9725457Abstract: Compounds of formula: in which R4 is chosen from substituted phenyl, optionally substituted naphthylene, optionally substituted anthracene and optionally substituted aromatic heterocycle, are useful as analgesics.Type: GrantFiled: May 19, 2014Date of Patent: August 8, 2017Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Gavril Pasternak, Susruta Majumdar
-
Patent number: 9718828Abstract: Provided are 6-5 membered fused pyridine ring compounds according to Formula (I) or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and their use in therapy. In particular, provided is the use of 6-5 membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.Type: GrantFiled: August 30, 2016Date of Patent: August 1, 2017Assignees: MERCK SHARP & DOHME CORP., MERCK SHARP & DOHME B.V.Inventors: Adrianus Petrus Antonius De Man, Jan-Gerard Sterrenburg, Hans C. A. Raaijmakers, Allard Kaptein, Arthur A. Oubrie, Johannes Bernardus Maria Rewinkel, Christiaan Gerardus Johannes Maria Jans, Jacobus C. H. M. Wijkmans, Tjeerd A. Barf, Alan B. Cooper, Ronald M. Kim, Sobhana Babu Boga, Hugh Y. Zhu, Xiaolei Gao, Xin Yao, Rajan Anand, Hao Wu, Shilan Liu, Chundao Yang, Abdul-Basit Alhassan, James Wang, Younong Yu, Jian Liu, Henry M. Vaccaro
-
Patent number: 9708278Abstract: In one aspect, the invention relates to N-substituted 3,4-dihydro-benzo[£][1,4]oxazine-2-carboxamide analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor M1 (mAChR M1); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: GrantFiled: November 18, 2014Date of Patent: July 18, 2017Assignee: Vanderbilt UniversityInventors: Craig W. Lindsley, P. Jeffrey Conn, Shaun R. Stauffer, Joseph D. Panarese
-
Patent number: 9708315Abstract: The present invention relates to novel 1,2,4-triazolo[4,3-a]pyridine compounds as positive allosteric modulators (PAMs) of the metabotropic glutamate receptor subtype 2 (“mGluR2”). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which mGluR2 subtype of metabotropic receptors is involved.Type: GrantFiled: September 3, 2014Date of Patent: July 18, 2017Assignee: Janssen Pharmaceutica NVInventors: José Maria Cid-Núñez, Andrés Avelino Trabanco-Suárez, Marc André Ceusters, Hilde Lavreysen
-
Patent number: 9708320Abstract: A diazabicyclooctane compound, which is a beta-lactame inhibitor, represented by the following formula (I): wherein A represents Ra(Rb)N— or RcO—; B represents NH or NC1-6 alkyl; C represents benzyl, H or SO3M, wherein M represents H, an inorganic or an organic cation; Ra and Rb represent H, C1-6 alkyl or acyl; Rc represents C1-6 alkyl or a heterocyclyl; A is unsubstituted or substituted with 0 to 4 substituents Fn1, wherein Fn1 represents C1-6 alkyl, O?, or Rg-(CH2)0-3—, wherein Rg represents a heterocyclyl, phenyl, heteroaryl, acyl, RdO2S—, Re(Rf)N—, Re(Rf)NCO—, ReO—, ReOCO— or a protective group, wherein Rd represents C1-6 alkyl or MO—; Re and Rf represent H or C1-6 alkyl, and a heterocycle having at least one nitrogen atom may be formed between Ra and Rb, between Rc and B, or between Re and Rf.Type: GrantFiled: October 1, 2015Date of Patent: July 18, 2017Assignee: MEIJI SEIKA PHARMA CO., LTD.Inventors: Takao Abe, Takeshi Furuuchi, Yoshiaki Sakamaki, Seiichi Inamura, Akihiro Morinaka
-
Patent number: 9701666Abstract: The present invention relates to 1,4-pyridone bicyclic heteroaryl compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.Type: GrantFiled: December 20, 2013Date of Patent: July 11, 2017Assignee: Epizyme, Inc.Inventors: Kevin W. Kuntz, John Emmerson Campbell
-
Patent number: 9688678Abstract: The present invention relates to novel substituted oxindole derivatives of the formula I wherein A is a ring selected from phenyl and 6-membered hetaryl containing 1 or 2 nitrogen atoms as ring members, where ring A carries one substituent R6 and optionally one substituent R7; B is a ring selected from phenyl and a monocyclic or bicyclic heteroaromatic ring containing 1, 2 or 3 heteroatoms selected from O, N and S as ring members, where ring B may carry 1, 2 or 3 substituents R8; X1, X2, X3 and X4, independently of each other, are selected from —CH2—, —O—, —S(O)c—, —NH—, —C(O)—, —CH2CH2—, —CH2O—, —OCH2—, —S(O)cCH2—, —CH2S(O)c—, CH2NH—, —NHCH2—, —CH2C(O)— and C(O)CH2—; X5 is NH, CH2 or O; and wherein c, R1, R2, (R3)a, (R4)b, R5, R6, R7, and R8 are as defined in the claims. The present invention also relates to pharmaceutical compositions comprising the novel substituted oxindole derivatives of the formula I, and to their use for the treatment of vasopressin-related disorders.Type: GrantFiled: May 15, 2015Date of Patent: June 27, 2017Assignee: AbbVie Deutschland GmbH & Co. KGInventors: Hervé Geneste, Wilfried Hornberger, Katja Jantos, Andreas Kling, Marcel Van Gaalen
-
Patent number: 9682985Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein GAr, L1, Z1 and Z2 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.Type: GrantFiled: March 14, 2016Date of Patent: June 20, 2017Assignee: AbbVie Inc.Inventors: Jerome Daanen, David DeGoey, Jennifer M. Frost, Tammie Jinkerson, Steve Latshaw, Lei Shi
-
Patent number: 9657022Abstract: Compounds of Formula (I), their preparation, and use in preventing or treating a bacterial infection are disclosed.Type: GrantFiled: January 21, 2015Date of Patent: May 23, 2017Assignee: WOCKHARDT LIMITEDInventors: Sanjay Raikar, Sanjay Kisan Dabhade, Laxmikant Pavase, Sachin Bhagwat, Ravindra Dattatraya Yeole, Mahesh Vithalbhai Patel
-
Patent number: 9643980Abstract: Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.Type: GrantFiled: July 1, 2016Date of Patent: May 9, 2017Assignee: Genentech, Inc.Inventors: Marie-Gabrielle Braun, Emily Hanan, Steven T. Staben, Robert Andrew Heald, Calum MacLeod, Richard Elliott
-
Patent number: 9611269Abstract: The present invention provides azetidinyl phenyl, pyridyl, or pyrazinyl carboxamide derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase (JAKs) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.Type: GrantFiled: April 27, 2015Date of Patent: April 4, 2017Assignees: Incyte Corporation, Incyte Holdings CorporationInventors: Wenqing Yao, David Burns, Jincong Zhuo
-
Patent number: 9604976Abstract: The present invention provides a compound of the following formula, salts, racemates, diastereomers, enantiomers, esters, carbamates, phosphates, sulfates, deuterated forms and prodrugs thereof. Also provided is the use of these compounds as antibacterials, compositions comprising them and processes for their manufacture.Type: GrantFiled: March 21, 2013Date of Patent: March 28, 2017Assignee: SPERO GYRASE, INC.Inventors: Christopher James Lunniss, James T. Palmer, Gary Robert William Pitt, Lorraine Claire Axford, David Davies
-
Patent number: 9597317Abstract: The present invention relates to substituted indazole compounds which modulate the activity of protein kinases and are therefore useful in treating diseases caused by degulated protein kinase activity, like cancer. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such these compounds or the pharmaceutical compositions containing them.Type: GrantFiled: July 6, 2016Date of Patent: March 21, 2017Assignee: NERVIANO MEDICAL SCIENCES S.R.L.Inventors: Andrea Lombardi Borgia, Marina Ciomei, Daniele Donati, Marcella Nesi
-
Patent number: 9598440Abstract: The present invention relates to compounds which modulate interleukin-1 (IL-1) receptor-associated kinase 4 (IRAK4) and are useful in the prevention or treatment of inflammatory, cell proliferative and immune-related conditions and diseases. Specifically, provided herein are inhibitors of IRAK4 of Formula I and pharmaceutical compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.Type: GrantFiled: October 3, 2013Date of Patent: March 21, 2017Assignee: MERCK SHARP & DOHME CORP.Inventors: W. Michael Seganish, William T. McElroy, Stephanie Brumfield, R. Jason Herr, Larry Yet, Jinhai Yang, James P. Harding, III, Ginny Dai Ho, Deen Tulshian, Wensheng Yu, Michael K.C. Wong, Brian Lavey, Joseph A. Kozlowski
-
Patent number: 9567316Abstract: Described herein are aminoquinoline and aminoacridine based hybrids, pharmaceutical compositions and medicaments that include such aminoquinoline and aminoacridine based hybrids, and methods of using such compounds for diagnosing and/or treating infections, neurodegerative diseases or disorders, inflammation, inflammation associated diseases and disorders, and/or diseases or disorders that are treatable with dopamine agonists such as the restless leg syndrome.Type: GrantFiled: February 28, 2013Date of Patent: February 14, 2017Assignees: THE MCLEAN HOSPITAL CORPORATION, UNIVERSITY OF DELHIInventors: Diwan S. Rawat, Sunny Manohar, Ummadisetty Chinna Rajesh, Deepak Kumar, Anuj Thakur, Mohit Tripathi, Panyala Linga Reddy, Shamseer Kulangara Kandi, Satyapavan Vardhineni, Kwang-Soo Kim, Chun-Hyung Kim
-
Patent number: 9556126Abstract: Provided herein are diaminopyrimidyl Compounds having the following structures: wherein X, L, R1, and R2 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidyl Compound, and methods for treating or preventing PKC-theta-mediated disorders, or a condition treatable or preventable by inhibition of a kinase, for example, PKC-theta.Type: GrantFiled: December 19, 2014Date of Patent: January 31, 2017Assignee: Signal Pharmaceuticals, LLCInventors: Patrick Papa, Brian Edwin Cathers, Andrew Antony Calabrese, Brandon Wade Whitefield, Brydon Bennett, Daniel Cashion, Deborah Mortensen, Dehua Huang, Eduardo Torres, Jason Parnes, John Sapienza, Joshua Hansen, Katerina Leftheris, Matthew Correa, Maria Mercedes Delgado, Raj K. Raheja, Sogole Bahmanyar, Sayee Hegde, Stephen Norris, Veronique Plantevin-Krenitsky
-
Patent number: 9546158Abstract: The invention relates to novel substituted condensed pyrimidine compounds of general formula (I) in which the chemical groupings, substituents and indices are as defined in the description, and to their use as medicaments, in particular as medicaments for the treatment of conditions and diseases that can be treated by inhibition of the PDE4 enzyme.Type: GrantFiled: July 15, 2015Date of Patent: January 17, 2017Assignee: GRUENENTHAL GMBHInventors: Antonio Nardi, Florian Jakob, Ingo Konetzki, Tobias Craan, Christian Hesslinger
-
Patent number: 9540367Abstract: The present invention in one embodiment provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula I are as defined in the specification.Type: GrantFiled: August 15, 2013Date of Patent: January 10, 2017Assignee: Concert Pharmaceuticals, Inc.Inventor: Roger D. Tung
-
Patent number: 9512121Abstract: Provided are [1,2,4]triazol[4,3-a]pyridine derivatives as shown in the general formula (I), a preparation method therefor, and a pharmaceutical composition containing the derivative, wherein the pharmaceutical composition is used as a therapeutic agent, and especially used as a c-Met inhibitor and an immunosuppressant. Each substituent in the general formula (I) is the same as that defined in the specification.Type: GrantFiled: March 4, 2014Date of Patent: December 6, 2016Assignee: Jiangsu Hansoh Pharmaceutical Co., Ltd.Inventors: Zhiming Zhao, Haiyang Wang, Chenchen Wu, Qingqing Qi
-
Patent number: 9505755Abstract: The present invention provides a compound of formula I: a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.Type: GrantFiled: August 8, 2014Date of Patent: November 29, 2016Assignee: NOVARTIS AGInventors: Christopher Michael Adams, Veronique Darsigny, Alec Nathanson Flyer, Christine Fang Gelin, Timothy Brian Hurley, Nan Ji, Rajeshri Ganesh Karki, Toshio Kawanami, Erik Meredith, Chang Rao, Michael H. Serrano-Wu, Catherine Fooks Solovay
-
Patent number: 9469644Abstract: This application discloses compounds according to generic Formula (I) wherein all variables are defined as described herein, which inhibit BTK. The compounds disclosed herein are useful to modulate the activity of BTK and treat diseases associated with excessive BTK activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula (I) and at least one carrier, diluent or excipient.Type: GrantFiled: March 3, 2014Date of Patent: October 18, 2016Assignee: Hoffmann-La Roche Inc.Inventors: Javier De Vicente Fidalgo, Romyr Dominique, Francisco Javier Lopez-Tapia, Sung-Sau So
-
Patent number: 9464055Abstract: The present invention is directed to quinoline derivatives, pharmaceutical compositions containing said derivatives and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, in the treatment of disorders and conditions responsive to inverse agonism of the CB-1 receptor. For example, the compounds of the present invention are useful in the treatment of metabolic disorders.Type: GrantFiled: February 6, 2015Date of Patent: October 11, 2016Assignee: Janssen Pharmaceutica NVInventors: Bart DeCorte, Mark Macielag, Michael Greco, Yue-Mei Zhang, Christopher Teleha
-
Patent number: 9458152Abstract: The present invention provides compounds of Formula I, and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.Type: GrantFiled: October 22, 2015Date of Patent: October 4, 2016Assignee: Amgen Inc.Inventors: Matthew Weiss, Alessandro Boezio, Christiane Boezio, John R. Butler, Margaret Yuhua Chu-Moyer, Erin F. Dimauro, Thomas Dineen, Russell Graceffa, Angel Guzman-Perez, Hongbing Huang, Charles Kreiman, Daniel La, Isaac E. Marx, Benjamin Charles Milgram, Hanh Nho Nguyen, Emily Anne Peterson, Karina R. Vaida, Brian Sparling
-
Patent number: 9446040Abstract: Imidazoquinolines of formula I that contain substituted amine or amide functionality at 1-position and that are effective as Toll like Receptor 7 activators are disclosed. These compounds are useful as anticancer agents.Type: GrantFiled: June 3, 2015Date of Patent: September 20, 2016Assignee: 4SC AGInventors: Volker Gekeler, Thomas Maier, Astrid Zimmermann, Hans-Peter Hofmann, Sanjeev A. Kulkarni, Anil P. Jagtap, Ganesh S. Chaure
-
Patent number: 9439896Abstract: The invention relates to new quinoline derivative compounds of formula (I), to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.Type: GrantFiled: October 26, 2012Date of Patent: September 13, 2016Assignee: ASTEX THERAPEUTICS LTDInventors: Valerio Berdini, Patrick Rene Angibaud, Steven John Woodhead, Gordon Saxty
-
Patent number: 9440969Abstract: Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on each of B-Raf, B-Raf V600E and c-Raf-1 protein kinase. In certain aspects and embodiments, the described compounds are active in inhibiting proliferation of a Ras mutant cell line.Type: GrantFiled: October 14, 2014Date of Patent: September 13, 2016Assignee: Plexxikon Inc.Inventors: Prabha N. Ibrahim, Guoxian Wu, Jack Lin, Wayne Spevak, Hanna Cho, Todd Ewing, Chao Zhang
-
Patent number: 9433613Abstract: Pharmaceutical compositions and methods for treating bacterial infections are disclosed.Type: GrantFiled: January 13, 2014Date of Patent: September 6, 2016Assignee: WOCKHARDT LIMITEDInventors: Mahesh Vithalbhai Patel, Sachin Bhagwat, Prasad Keshav Deshpande
-
Patent number: 9422290Abstract: Disclosed are compounds of general formula (I) wherein the groups R1 to R3 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.Type: GrantFiled: November 11, 2013Date of Patent: August 23, 2016Assignee: Boehringer Ingelheim International GmbHInventors: Harald Engelhardt, Davide Gianni, Dirk Kessler, Ulrich Reiser, Christian Smethurst, Andreas Steffen
-
Patent number: 9393239Abstract: A compound of formula (I): wherein: M is hydrogen or a pharmaceutically acceptable salt-forming cation; Y is OR1 or NR2R3, and R1, R2, R3 and M are as defined herein. Also, methods of treating bacterial infection, pharmaceutical compositions, molecular complexes and processes for preparing compounds.Type: GrantFiled: April 15, 2014Date of Patent: July 19, 2016Assignee: FEDORA PHARMACEUTICALS INC.Inventors: Samarendra N. Maiti, Dai Nguyen, Jehangir Khan, Rong Ling
-
Patent number: 9394309Abstract: The present application relates to novel 1-phenyl-1H-imidazo[1,2-b]pyrazole derivatives, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular angiogenic disorders and hyperproliferative disorders, where neovascularization plays a role, such as, for example, neoplastic disorders and tumor disorders. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.Type: GrantFiled: January 23, 2013Date of Patent: July 19, 2016Assignees: Bayer Pharma Aktiengesellschaft, Bayer Intellectual Property GmbHInventors: Frank Süβmeier, Mario Lobell, Sylvia Grünewald, Michael Härter, Bernd Buchmann, Joachim Telser, Hannah Jöriβen, Melanie Heroult, Antje Kahnert, Klemens Lustig, Niels Lindner
-
Patent number: 9382231Abstract: The present invention provides compounds of Formula I: or pharmaceutically acceptable salts thereof, as well as their compositions and methods of use, that inhibit the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.Type: GrantFiled: May 16, 2014Date of Patent: July 5, 2016Assignee: Incyte CorporationInventors: Yun-Long Li, Jincong Zhuo, Ding-Quan Qian, Song Mei
-
Patent number: 9382243Abstract: Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK activated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.Type: GrantFiled: August 16, 2013Date of Patent: July 5, 2016Assignee: Merck Sharp & Dohme Corp.Inventors: James M. Apgar, Tesfaye Biftu, Ping Chen, Danqing Feng, Jacqueline D. Hicks, Ahmet Kekec, Kenneth J. Leavitt, Bing Li, Iyassu Sebhat, Xiaoxia Qian, Lan Wei, Robert R. Wilkening, Zhicai Wu
-
Patent number: 9371321Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating immunological disorders, cardiovascular disease, cancer, and other diseases, disorders or conditions associated with PI3K?.Type: GrantFiled: January 8, 2015Date of Patent: June 21, 2016Assignee: AstraZeneca ABInventors: Edcon Chang, Christopher Smith, Xiaolun Wang, Michael B. Wallace
-
Patent number: 9359380Abstract: The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.Type: GrantFiled: March 12, 2014Date of Patent: June 7, 2016Assignee: Vertex Pharmaceuticals IncorporatedInventors: John Patrick Maxwell, Paul S. Charifson, Qing Tang, Steven M. Ronkin, Katrina Lee Jackson, Albert Charles Pierce, David J. Lauffer, Pan Li, Simon Giroux, Jinwang Xu, Kevin M. Cottrell, Mark A. Morris, Nathan D. Waal, John J. Court, Wenxin Gu, Hongbo Deng
-
Patent number: 9353116Abstract: The present invention sets forth a new chemical genetic approach for engineering kinase enzymes with a cysteine gatekeeper residue as well as for developing electrophilic inhibitors thereto. The present invention also provides a Src proto-oncogenic tyrosine kinase with a cysteine gatekeeper that recapitulates wild type activity and can be irreversibly inhibited both in vitro and in cells. The present invention also provides methods and compositions for modulating kinases and for treating kinase-associate diseases.Type: GrantFiled: November 30, 2012Date of Patent: May 31, 2016Assignee: The Regents of the University of CaliforniaInventors: Adam L. Garske, Kevan M. Shokat